A Phase 2 interventional study of LDV/SOF and SOF in Chronic HCV Infection, sponsored by Gilead Sciences. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-06.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with genotypes 1 and 4 hepatitis C virus (HCV) infection and sofosbuvir (SOF) plus ribavirin (RBV) in participants with genotypes 2 and 3 HCV infection. Participants with an inherited bleeding disorder and chronic HCV infection (either monoinfected or HIV-1/HCV coinfected) will be enrolled.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For -1/HCV co-infected individuals:
Exclusion Criteria:
Current or prior history of any of the following:
For HIV-1/HCV co-infected individuals:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
Drug: LDV/SOF
Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
Drug: SOF · Drug: RBV
Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
Drug: SOF · Drug: RBV
90/400 mg FDC tablet administered orally
Also known as: Harvoni®, GS-5885/GS-7977
400 mg tablet administered orally once daily
Also known as: Sovaldi®, GS-7977, PSI-7977
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame: Up to 24 weeks
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
Time frame: Posttreatment Week 4
Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With Virologic Failure
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
Time frame: Up to Posttreatment Week 24
Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL at Weeks 4, 8, 12, 16, 20, and 24 (HIV-1/HCV Co-infected Participants Only)
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Change From Baseline in Serum Creatinine at the End of Treatment and at Posttreatment Week 12 (HIV-1/HCV Co-infected Participants Only)
Time frame: Baseline; Weeks 12, 24, and Posttreatment Week 12
Participants were enrolled at study sites in the United States. The first participant was screened on 10 April 2014. The last study visit occurred on 17 August 2015.
| Milestone | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Started | 101 | 5 | 10 | 6 |
| Completed | 98 | 5 | 10 | 5 |
| Not completed | 3 | 0 | 0 | 1 |
| Withdrew: Enrolled but never treated | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| percentage of participants | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) | 99.0 (94.5 to 100.0) | 100.0 (47.8 to 100.0) | 100.0 (69.2 to 100.0) | 83.3 (35.9 to 99.6) |
| percentage of participants | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | 0 | 0 | 0 | 0 |
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
| percentage of participants | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4) | 99.0 (94.5 to 100.0) | 100.0 (47.8 to 100.0) | 100.0 (69.2 to 100.0) | 83.3 (35.9 to 99.6) |
| percentage of participants | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Week 1 | 28.3 | 20.0 | 20.0 | 16.7 |
| Week 2 | 68.7 | 40.0 | 70.0 | 33.3 |
| Week 4 | 94.9 | 100.0 | 100.0 | 66.7 |
| Week 8 | 100.0 | 100.0 | 100.0 | 100.0 |
| Week 12 | 99.0 | 100.0 | 100.0 | 100.0 |
| Week 16 | NA | 100.0 | NA | 100.0 |
| Week 20 | NA | 100.0 | NA | 100.0 |
| Week 24 | NA | 100.0 | NA | 100.0 |
| log10 IU/mL | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Baseline | 6.21 ± 0.673 | 6.02 ± 0.847 | 6.20 ± 1.002 | 6.6 ± 0.803 |
| Week 1 (LDV/SOF 12 Weeks: n= 98) | -4.41 ± 0.580 | -4.32 ± 0.815 | -4.39 ± 0.633 | -3.95 ± 0.473 |
| Week 2 (LDV/SOF 24 Week: n=4) | -4.87 ± 0.642 | -4.65 ± 0.967 | -5.01 ± 0.965 | -4.76 ± 0.797 |
| Week 4 | -5.05 ± 0.662 | -4.87 ± 0.847 | -5.05 ± 1.002 | -5.26 ± 0.786 |
| Week 8 | -5.06 ± 0.673 | -4.87 ± 0.847 | -5.05 ± 1.002 | -5.45 ± 0.803 |
| Week 12 (LDV/SOF 12 Weeks: n= 98) | -5.06 ± 0.675 | -4.87 ± 0.847 | -5.05 ± 1.002 | -5.45 ± 0.803 |
| Week 16 | NA ± NA | -4.87 ± 0.847 | NA ± NA | -5.45 ± 0.803 |
| Week 20 | NA ± NA | -4.87 ± 0.847 | NA ± NA | -5.45 ± 0.803 |
| Week 24 | NA ± NA | -4.87 ± 0.847 | NA ± NA | -5.45 ± 0.803 |
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
| percentage of participants | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Percentage of Participants With Virologic Failure | 0 | 0 | 0 | 16.7 |
| percentage of participants | LDV/SOF 12 Weeks GT1 or GT4 | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|
| Week 4 | 100 | 100 | 100 |
| Week 8 | 100 | 100 | 100 |
| Week 12 | 100 | 100 | 100 |
| Week 16 | NA | NA | 100 |
| Week 20 | NA | NA | 100 |
| Week 24 | NA | NA | 66.7 |
| mg/dL | LDV/SOF 12 Weeks GT1 or GT4 | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|
| Baseline | 0.94 ± 0.197 | 1.01 ± 0.118 | 0.94 ± 0.086 |
| Week 12 | 0.04 ± 0.079 | -0.03 ± 0.095 | -0.03 ± 0.093 |
| Week 24 | NA ± NA | NA ± NA | -0.08 ± 0.069 |
| Posttreatment Week12 | -0.01 ± 0.113 | -0.08 ± 0.015 | -0.02 ± 0.081 |
Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDV/SOF 12 Weeks GT1 or GT4 | — | 5/99 (5.1%) | 54/99 (54.5%) |
| LDV/SOF 24 Weeks GT1 (TE) | — | 0/5 (0%) | 3/5 (60%) |
| SOF+RBV 12 Weeks GT2 | — | 0/10 (0%) | 8/10 (80%) |
| SOF+RBV 24 Weeks GT3 | — | 1/6 (16.7%) | 4/6 (66.7%) |
| Event | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 0/99 | 0/5 | 0/10 | 1/6 |
| HaemarthrosisMusculoskeletal and connective tissue disorders | 2/99 | 0/5 | 0/10 | 0/6 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/99 | 0/5 | 0/10 | 0/6 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/99 | 0/5 | 0/10 | 0/6 |
| Suicidal ideationPsychiatric disorders | 1/99 | 0/5 | 0/10 | 0/6 |
| Miscarriage of partnerSocial circumstances | 1/99 | 0/5 | 0/10 | 0/6 |
| HaematomaVascular disorders | 1/99 | 0/5 | 0/10 | 0/6 |
| Event | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/99 | 0/5 | 1/10 | 3/6 |
| InsomniaPsychiatric disorders | 6/99 | 0/5 | 1/10 | 3/6 |
| ConstipationGastrointestinal disorders | 1/99 | 2/5 | 0/10 | 0/6 |
| FatigueGeneral disorders | 29/99 | 1/5 | 3/10 | 2/6 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/99 | 0/5 | 1/10 | 2/6 |
| HeadacheNervous system disorders | 14/99 | 0/5 | 3/10 | 0/6 |
| Food poisoningGastrointestinal disorders | 0/99 | 1/5 | 0/10 | 0/6 |
| Influenza like illnessGeneral disorders | 1/99 | 1/5 | 0/10 | 0/6 |
| Muscle strainInjury, poisoning and procedural complications | 1/99 | 1/5 | 0/10 | 0/6 |
| HaemorrhageVascular disorders | 0/99 | 1/5 | 0/10 | 0/6 |
Safety Analysis Set: participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| Mean | 44 ± 11.1 | 49 ± 11.1 | 48 ± 13.8 | 47 ± 6.7 | 45 ± 11.1 |
| Sex: Female, Male(Participants) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| Female | 6 | 0 | 1 | 0 | 7 |
| Male | 93 | 5 | 9 | 6 | 113 |
| Ethnicity (NIH/OMB)(Participants) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 1 | 0 | 5 |
| Not Hispanic or Latino | 95 | 5 | 9 | 6 | 115 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| Black or African American | 18 | 1 | 1 | 0 | 20 |
| White | 75 | 4 | 8 | 5 | 92 |
| Asian | 4 | 0 | 1 | 1 | 6 |
| Other | 2 | 0 | 0 | 0 | 2 |
| Cirrhosis Status(participants) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| No | 71 | 0 | 8 | 4 | 83 |
| Yes | 28 | 5 | 2 | 2 | 37 |
| HCV Genotype(participants) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| Genotype 1 | 98 | 5 | 0 | 0 | 103 |
| Genotype 2 | 0 | 0 | 10 | 0 | 10 |
| Genotype 3 | 0 | 0 | 0 | 6 | 6 |
| Genotype 4 | 1 | 0 | 0 | 0 | 1 |
| HCV RNA(log10 IU/mL) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| Mean | 6.2 ± 0.67 | 6.0 ± 0.85 | 6.2 ± 1.00 | 6.6 ± 0.80 | 6.2 ± 0.71 |
| HCV RNA Category(participants) | LDV/SOF 12 Weeks GT1 or GT4 | LDV/SOF 24 Weeks GT1 (TE) | SOF+RBV 12 Weeks GT2 | SOF+RBV 24 Weeks GT3 | Total |
|---|---|---|---|---|---|
| < 800,000 IU/mL | 23 | 2 | 2 | 1 | 28 |
| ≥ 800,000 IU/mL | 76 | 3 | 8 | 5 | 92 |
2 further baseline measures are reported on the registry.
The record gives a start of Apr 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Ribavirin